Clinical Trial Update: A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial to assess tolerability of BI 3802876 in adults with compensated liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cirrhosis
• Metabolic Dysfunction-associated Steatohepatitis

Drugs mentioned

• BI 3802876

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Liver Cirrhosis | Phase 2 | Status: RECRUITING